Replimune has announced a workforce reduction and scaling back of its U.S. manufacturing operations. This decision follows the FDA's rejection of its lead asset, RP1. The drug was targeted at treating a type of skin cancer known as melanoma.
What happened
Replimune was forced to reduce its workforce after the FDA declined to approve its drug RP1, which was intended to treat melanoma.
How many employees affected
The exact number of employees affected by the workforce reduction was not disclosed in the announcement.
Why layoffs happened
The layoffs are a direct consequence of the FDA's decision not to approve Replimune's lead drug candidate, RP1.
Company background
Replimune is a biotechnology company focused on developing oncolytic immunotherapies to treat cancer. Its lead product candidate was RP1, targeting melanoma.
Industry impact
The FDA's rejection of RP1 is a setback for Replimune and potentially impacts the melanoma treatment landscape. The company is scaling back its manufacturing operations as a result.
What's next
Replimune will scale back U.S. manufacturing operations. The company has not yet announced further details regarding its future plans.
Source: seekingalpha.com